This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-30. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
== 1971–88 == South Africa was the indirect cause of the 1976 Olympic boycott. A New Zealand rugby union tour of South Africa prompted African countries to demand that the New Zealand Olympic team be excluded from the games. The IOC demurred on the grounds that rugby union was not an Olympic sport and the New Zealand Rugby Union was not affiliated to the New Zealand Olympic Committee. Of 28 African invitees, 26 boycotted the Games, joined by Iraq and Guyana. South Africa continued to compete at the (Summer) Paralympics until excluded by the Dutch government from the 1980 Games. The country had a racially desegregated parasport team from 1975. South Africa was expelled from the International Paralympic Committee in 1985. The IOC adopted a declaration against "apartheid in sport" on 21 June 1988, for the total isolation of apartheid sport.
The term flourishing, in positive psychology, refers to optimal human functioning. It comprises four parts: goodness, generativity, growth, and resilience (Fredrickson, 2005). According to Fredrickson (2005), goodness is made up of: happiness, contentment, and effective performance; generativity is about making life better for future generations, and is defined by "broadened thought-action repertoires and behavioral flexibility"; growth involves the use of personal and social assets; and resilience reflects survival and growth after enduring a hardship. A flourishing life stems from mastering all four of these parts. Two contrasting ideologies are languishing and psychopathology. On the mental health continuum, these are considered intermediate mental health disorders, reflecting someone living an unfulfilled and perhaps meaningless life. Those who languish experience more emotional pain, psychosocial deficiency, restrictions in regular activities, and missed workdays. Fredrickson & Losada (2005) conducted a study on university students, operationalizing positive and negative affect. Based on a mathematical model which has been strongly criticized, and now been formally withdrawn by Fredrickson as invalid, Fredrickson & Losada claimed to have discovered a critical positivity ratio, above which people would flourish and below which they would not.
== Fiber coatings == The coating on the SPME fiber can be selected to improve sensitivity for specific analytes of interest; ideally the sorbent layer will have a high affinity for the target analytes. There are many commercially available SPME fiber coatings that are combinations of polydimethylsiloxane, divinylbenzene, Carboxen, polyacrylate, and polyethylene glycol. However, one downside to many of the commercially available SPME fibers is that they tend to be physically brittle due to their composition. Depending on the characteristics of the target analytes, certain properties of the coating improve extraction such as polarity, thickness, and surface area. The sample matrix can also influence the fiber coating selection. Based on the sample and analytes of interest, the fiber may need to tolerate direct immersion as opposed to a headspace extraction. In one of the study the fiber coating method significantly enhances the performance of SPME by ensuring a high binding capacity and improved mass transfer efficiency. By preventing the ingress of the polymeric adhesive matrix into the pores of the sorbent particles, the method allows for faster adsorption and desorption times, which is crucial for high-throughput applications. Metal–organic frameworks (MOFs) have been investigated as sorbent materials for SPME coatings because their pore dimensions and surface functional groups can be modified to alter extraction affinity and selectivity.
=== RNA sequencing === RNA sequencing was one of the earliest forms of nucleotide sequencing. The major landmark of RNA sequencing is the sequence of the first complete gene and the complete genome of Bacteriophage MS2, identified and published by Walter Fiers and his coworkers at the University of Ghent (Ghent, Belgium), in 1972 and 1976. Traditional RNA sequencing methods require the creation of a cDNA molecule which must be sequenced.
Sources: en.wikipedia.org
=== Signaling pathways used in electrotaxis === In the absence of a complete explanation of the mechanism behind electrotaxis, certain signaling pathways have been found to have an involvement in electrotaxis. In both neutrophils and keratinocytes, Zhau et al. experimentally determined that physiological strength EFs induce phosphorylation of extracellular-signal-regulated kinase (ERK), p38 mitogen-activated Kinase (MAPK), Src, and Akt on ser 473. In chemotaxis, Src and Akt are polarized by phosphatidylinositol-3-OH kinase-γ (PI(3)Kγ) activation and inhibition of phosphate tensin homolog (PTEN). In the experiment, phosphorylated Src polarized in the direction of migration when influenced by physiological strength EFs, as is also seen in chemotaxis. Phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P3), another molecule used in signaling, polarized to the leading edge of HL60 cells when subjected to an EF. Upon reversal of the EF, polarization PtdIns(3,4,5)P3 rapidly reversed to the new direction of migration. Treatment with lantruculin did not prevent this from occurring, indicating that polarization is not actin-dependent. Cells in which the gene encoding PI(3)Kγ, Pik3cg, was disrupted exhibited reduced electrotaxic responses. Pharmocological inhibition of PI(3)K in keratinocytes produced the same results. Similarly, genetic disruption of PTEN resulted in increased phosphorylation of ERK and Akt and a greater electrotaxic response. Consideration of these results suggests that PI(3)Kγ and PTEN are involved in the signaling pathway used in electrotaxis.
Mavatrep (JNJ‐39439335) is a TRPV1 receptor selective competitive antagonist. It is an investigational analgesic that may be a potential treatment for pain and/or inflammation. Phase I trials have been completed in healthy Japanese and Caucasian volunteers. Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.
==== Increasing protein intake ==== A high protein diet relative to a low-fat or high-carbohydrate diet may increase thermogenesis and decrease appetite leading to weight reduction, particularly 3-6 months into a diet when rapid weight loss is observed. However, these advantages may be reduced later at 12–24 months into a diet during the slow weight loss phase.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.